

Tell me we've got a plan

RELAY

A pivotal phase III trial of CYRAMZA + erlotinib in previously untreated patients with EGFR mut+ mNSCLC⁶

RELAY^{6,12}

Global, multicenter, randomized, placebo-controlled, double-blind, phase III trial

Primary Endpoint

Investigator-assessed PFS

Select Secondary Endpoints

OS, ORR, DCR, DoR*

Key Inclusion Criteria¹²

- mNSCLC EGFR mutation (exon 21 [L858R] mutation or exon 19 deletion)
- Stage IV NSCLC
- ECOG PS 0/1

Key Stratification Factors¹²

- Geographic region (East Asia or other)
- Sex
- EGFR testing method
- EGFR mutation (exon 21 mutation or exon 19 deletion)

Key Exclusion Criteria^{12,13}

- Known EGFR T790M mutation
- Prior treatment with an EGFR-TKI or chemotherapy
- CNS metastases

↓
1:1 RANDOMIZATION
↓

CYRAMZA^{6,12}

10 mg/kg IV Q2W

+

Erlotinib

150 mg orally once daily

(n=224)

Placebo^{6,12}

IV Q2W

+

Erlotinib

150 mg orally once daily

(n=225)

*DoR is defined as time from first documented response to the date of objective progression or the date of death, whichever is earlier.

CNS=central nervous system; ECOG=Eastern Cooperative Oncology Group; IV=intravenous; OS=overall survival; PS=performance status; Q2W=every 2 weeks.

standing on the sidelines isn't for me

Patients in the RELAY trial may be similar to your patients with EGFR mut+ mNSCLC

Clinical and nonclinical characteristics of a patient suited for treatment with CYRAMZA + erlotinib^{12,13}

- Exon 21 (L858R) substitution mutation
- No prior treatment with TKIs for metastatic disease
- ECOG PS 0/1
- No brain metastases
- Nonsmoker
- Forward-thinking and determined to start on a targeted treatment plan

Does this patient with EGFR mut+ mNSCLC sound familiar to you?



RELAY: Baseline characteristics¹²

		CYRAMZA + erlotinib (n=224)	Placebo + erlotinib (n=225)
Sex, n (%)	Female	141 (63)	142 (63)
	Male	83 (37)	83 (37)
Age	Median (IQR), years	65 (57–71)	64 (56–70)
Race,* n (%)	Asian	172 (77)	174 (77)
	White	52 (23)	48 (21)
Smoking status, n (%)	Never	134 (60)	139 (62)
ECOG PS, n (%)	0	116 (52)	119 (53)
	1	108 (48)	106 (47)
Disease stage at diagnosis, n (%)	Stage IV NSCLC	195 (87)	189 (84)
	Other	29 (13)	36 (16)
EGFR mutation type, n (%)	Exon 19 deletion	123 (55)	120 (53)
	Exon 21 (L858R) mutation	99 (44)	105 (47)
EGFR testing method, n (%)	<i>therascreen</i> [®] or <i>cobas</i> [®]	96 (43)	101 (45)
	Other	127 (57)	124 (55)

*Placebo + erlotinib arm included 3 other: American Indian or Alaska Native, Black or African American, and missing.¹⁴
IQR=interquartile range.
Reprinted from *Lancet Oncol*, doi:10.1016/S1470-2045(19)30634-5, Nakagawa K, Garon EB, Seto T, et al, Copyright (2019), with permission from Elsevier.